Abbott Laboratories SEC filings document an Illinois healthcare company with common shares listed under ABT and operations in diagnostics, medical devices, nutritionals and branded generic medicines. The filings include Form 8-K reports on operating results, non-GAAP financial measures, material agreements, acquisition-related events, debt financing and amendments to corporate governance documents.
Abbott's proxy and event filings cover shareholder voting matters, board and bylaw governance, executive compensation, capital-structure disclosures and clinical or regulatory disclosures. The filing record also documents the completed Exact Sciences acquisition and the addition of cancer diagnostics to Abbott's broader diagnostic portfolio.
Abbott Laboratories executive reports insider holdings
An executive vice president of Abbott Laboratories filed an ownership report as of 12/12/2025. The insider directly holds 63,621 common shares of Abbott Laboratories. In addition, the report lists several employee stock options granted under the Abbott Laboratories 2017 Incentive Stock Program, all classified as direct holdings.
The options cover blocks of Abbott common shares with exercise prices ranging from $75.90 to $135.42 per share and expiration dates from 02/21/2029 through 02/24/20352024 and 2028, reflecting the vesting schedules tied to long-term incentive compensation.
Abbott Laboratories executive reports equity transaction in company stock. A reporting person serving as EVP and Group President of Abbott Laboratories (ticker ABT) filed a Form 4 covering activity on 12/11/2025. The filing shows a transaction in Abbott common shares without par value, coded "G" under the transaction code and marked as a disposition of 1,536 shares at a price of $123.28 per share.
Following this transaction, the reporting person is shown as beneficially owning 132,233 Abbott common shares in direct ownership form. The filing is made as an individual Form 4 for one reporting person and is signed by an attorney-in-fact on 12/12/2025.
Abbott Laboratories filed a Form 8-K announcing a governance update. On December 12, 2025, Nita Ahuja, M.D. was named to Abbott’s Board of Directors. On the same date, Abbott’s Board amended the first sentence of Article III, Section 2 of its by-laws so that the Board shall consist of thirteen directors, an increase from twelve, effective December 12, 2025. Abbott also filed its amended and restated by-laws as an exhibit, reflecting these changes.
The Vanguard Group has updated its ownership disclosure for Abbott Laboratories common stock. Vanguard reports beneficial ownership of 174,894,079 Abbott shares, representing 10.05 % of the outstanding common stock. Vanguard reports no sole voting power, with 10,372,669 shares subject to shared voting power, and the ability to dispose of 158,240,243 shares on a sole basis and 16,653,836 shares on a shared basis. The filing states that Vanguard holds these securities in the ordinary course of business as an investment adviser, not for the purpose of changing or influencing control of Abbott. Vanguard’s clients, including registered investment companies and other managed accounts, have the right to receive dividends and sale proceeds, and no single other person has an interest in more than 5 % of the class.
Abbott Laboratories reported an insider transaction by a senior executive. A Senior Vice President filed a Form 4 disclosing the sale of 1,586 common shares of Abbott Laboratories on 11/25/2025. The shares were sold at a weighted average price of $128.0218 per share, with individual trades executed in a range from $128.02 to $128.06.
Following this sale, the reporting person beneficially owns 30,384 Abbott common shares, held directly. The filing notes that detailed breakdowns of the individual sale prices within the reported range are available upon request from Abbott Laboratories, its security holders, or the SEC staff.
Abbott Laboratories (ABT) reported a planned sale of restricted stock under Rule 144. The filing covers the proposed sale of 1,586 shares of common stock through UBS Financial Services on the NYSE, with an indicated aggregate market value of $203,042 as of the notice. The filing notes that there were 1,738,871,947 shares of common stock outstanding, providing context for the size of the planned sale.
The shares to be sold come from vested restricted stock awards. Three separate restricted stock award vestings dated 02/28/2025 are listed, for 740, 250, and 596 common shares, all acquired from the issuer, with payment dated 11/25/2025 and the nature of payment shown as “N/A.” The notice includes the standard Rule 144 representation that the seller does not know of undisclosed material adverse information about Abbott’s current or prospective operations.
Abbott Laboratories reported that its U.S. and Puerto Rico stock retirement plans will undergo an administrative blackout period. The blackout is being implemented to make several plan administration changes, including switching the recordkeeper, changing the trustee for certain U.S. Plan funds, and changing the custodian for certain P.R. Plan funds.
During the blackout, participants in these plans will not be able to change contribution rates, reallocate or diversify investments (including Abbott common shares), or obtain loans, withdrawals, or distributions from their plan accounts. The blackout is expected to begin on December 24, 2025 at 12 p.m. CST and to end during the week of January 11, 2026.
Abbott also notified its directors and executive officers about the blackout and related restrictions on trading in Abbott common shares under Section 306 of the Sarbanes-Oxley Act and Regulation BTR. Additional information about the blackout, including its actual start and end dates, is available on request from Abbott for two years after it ends.
Abbott Laboratories announced a definitive agreement to acquire Exact Sciences through a cash merger. Each outstanding Exact Sciences common share will be converted at closing into the right to receive $105.00 in cash, subject to customary terms and tax withholding, with Exact Sciences becoming a wholly owned Abbott subsidiary.
The deal is conditioned on approval by holders of at least a majority of Exact Sciences shares, required regulatory clearances including expiration or termination of the Hart-Scott-Rodino waiting period, absence of legal restraints, and satisfaction of representations, covenants, and a no–material adverse effect condition on Exact Sciences. In connection with signing, Abbott obtained a commitment for up to $20,000,000,000 of senior unsecured bridge loans to support the transaction.
Abbott Laboratories filed its Q3 2025 report with steady profit and higher sales. Net sales were $11,369 million, up from $10,635 million a year ago, while diluted EPS held at $0.94. Year‑to‑date, sales reached $32,869 million and diluted EPS rose to $2.70 from $2.38. Operating earnings improved to $2,057 million, supported by Medical Devices growth (notably Diabetes Care and Electrophysiology) and stronger Established Pharmaceuticals, partly offset by lower COVID‑19 testing revenue.
Cash from operations was $6,251 million for the first nine months, funding $1,503 million of long‑term debt repayments and $3,086 million in dividends, with purchases of common shares of $591 million. The company recorded 2025 restructuring charges of $197 million and $25 million of asset impairments to streamline diagnostics and devices. Remaining performance obligations were $6.0 billion in Diagnostics and $436 million in Medical Devices. As of September 30, 2025, common shares outstanding were 1,738,871,947.
Abbott Laboratories reported its third-quarter 2025 results, noting that the information was furnished under Item 2.02 and accompanied by a press release as Exhibit 99.1.
The company highlighted the use of non-GAAP financial measures to evaluate ongoing business performance. These measures adjust for items that can be unusual or unpredictable, including acquisition-related expenses, restructuring actions, fair value changes in contingent consideration, certain regulatory costs, adjustments tied to prior recognition of a significant non-cash deferred tax benefit, tax benefits associated with specified items, net tax benefit from resolution of prior-year tax positions, and excess tax benefits from share-based compensation. They also exclude intangible amortization expense to show results excluding these costs. Management believes these metrics provide useful insight for investors, while cautioning they should be considered alongside GAAP results.